Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pre-Exposure Prophylaxis (PrEP) use has remained low among US women while significantly increasing among men who have sex with men. Besides lack of awareness, women face several social and structural barriers in gaining access to and using PrEP. METHODS: Four focus group discussions with 20 HIV-negative women who live in the Washington DC metropolitan area. RESULTS: The women expressed concerns about social and structural barriers to PrEP use. They were afraid that stigma related to using "HIV medicines" could affect PrEP use as well. They are worried that family and friends may question their reasons for taking anti-retrovirals and suspect that they were HIV-positive. They expected hostile reactions from male partners, including accusations of infidelity and introducing mistrust in their relationships. Communicating with health care providers about sexual matters in general and their need for PrEP in particular were identified as further barriers. Women reported that providers rarely ask about risk behaviors related to HIV acquisition; that short visits hinder establishing a trusting relationship to discuss sensitive matters. They were concerned that disclosure of risk behaviors may result in judgmental responses and harsh treatment from providers. Lastly, women were concerned that PrEP costs, including insurance coverage and copays, would keep PrEP out of their reach. While cognizant of the potential barriers, women were unwavering in their determination to find ways to circumvent challenges to PrEP access. CONCLUSION: Social and structural barriers may impede women's access to PrEP despite their own reported interest. Continued efforts to reduce HIV stigma, improve patient-provider relationships and ensure affordability of PrEP may increase the likelihood that women will use this important prevention modality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096 · cited 1×
“PrEP has demonstrated efficacy to prevent HIV transmission in clinical studies worldwide [4,5].”
BackgroundAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256 · cited 1×
“PrEP has demonstrated efficacy to prevent HIV transmission in clinical studies worldwide [4,5].”
BackgroundPreexposure Prophylaxis for HIV Infection among African Women
Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,603 · cited 2×
“This lack of awareness is further complicated by results from the VOICE and FEM-PrEP studies, which failed to demonstrate significant reductions in HIV seroconversion among women [12-14].”
BackgroundResultStigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward
Mahajan, A. P., Sayles, J. N., Patel, V. A., Remien, R. H., Sawires, S. R., Ortiz, D. J., Szekeres, G., & Coates, T. J. (2008) · AIDS · doi:10.1097/01.aids.0000327438.13291.62 · Cited by 1,404 · cited 2×
“, by seeking prophylaxis, a woman may associate herself with HIV and thus face stigma and selfdiscriminate by neglecting to talk to her healthcare provider about her risk behaviors; her family, friends and partner(s) may treat her poorly if she starts taking PrEP and she may become labeled and stereotyped as a woman a…”
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296 · cited 1×
“This lack of awareness is further complicated by results from the VOICE and FEM-PrEP studies, which failed to demonstrate significant reductions in HIV seroconversion among women [12-14].”
Vanable, P. A., Carey, M. P., Blair, D. C., & Littlewood, R. A. (2006) · AIDS and Behavior · doi:10.1007/s10461-006-9099-1 · Cited by 619 · cited 1×
“Furthermore, the experience of stigma is associated with internalization of negative social cues among HIV-positive individuals, leading to depression, which is in itself a risk factor of poor adherence to antiretroviral medications [29].”
BackgroundThe Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench
Bacon, M. C., von Wyl, V., Alden, C., Sharp, G., Robison, E., Hessol, N., Gange, S., Barranday, Y., Holman, S., Weber, K., et al. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.9.1013-1019.2005 · Cited by 520 · cited 4×
“Given the importance of these factors as identified by our participants, a similar social integration program may be beneficial for potential PrEP users in the United States.”
BackgroundInfluentialSelf-citationVolk, J. E., Marcus, J. L., Phengrasamy, T., Blechinger, D., Nguyen, D. P., Follansbee, S., & Hare, C. B. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ778 · Cited by 489
Auerbach, J. D., Kinsky, S., Brown, G., & Charles, V. (2015) · AIDS Patient Care and STDs · doi:10.1089/apc.2014.0142 · Cited by 392 · cited 4×
“study found that while HIV-negative women were interested in PrEP, they identified mistrust of medical professionals and social stigma as two of the most important barriers to PrEP uptake [11].”
BackgroundInfluentialPatterson, K. B., Prince, H. A., Kraft, E., Jenkins, A. J., Shaheen, N. J., Rooney, J. F., Cohen, M. S., & Kashuba, A. D. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003174 · Cited by 355 · cited 1×
“On the other hand, further research has highlighted the need for high levels of adherence among women to achieve adequate drug levels in the female genital tract tissue [15] providing additional biologic basis for the lack of efficacy that was reported in the VOICE and Fem-PrEP studies.”
Background
Cited by
Velloza, J., Khoza, N., Scorgie, F., Chitukuta, M., Mutero, P., Mutiti, K., Mangxilana, N., Nobula, L., Bulterys, M. A., Atujuna, M., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25463 · Cited by 214
Metadata
- Authors
- Goparaju, L., Praschan, N. C., Jeanpiere, L. W., Experton, L. S., Young, M. A., & Kassaye, S.
- Venue
- Journal of AIDS & Clinical Research
- Publisher
- OMICS Publishing Group
- Published
- 2017
- Volume
- 08
- Issue
- 09
- ISSN
- 2155-6113 (ISSN-L)
- OpenAlex
- W2762536000
- Cited by
- 227
- References
- 36
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women. https://app.cochat.ai/papers/10.4172/2155-6113.1000730
- The paper
- Goparaju, L., Praschan, N. C., Jeanpiere, L. W., Experton, L. S., Young, M. A., & Kassaye, S. (2017). Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women. Journal of AIDS & Clinical Research. https://doi.org/10.4172/2155-6113.1000730
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.